Genetic susceptibility to multiple sclerosis is implicated on the basis of classical family studies and phenotype analyses. The only reproducible legacy from the candidate gene approach has been the discovery of population associations with alleles of the major histocompatibility complex. Systematic genome scanning has since been applied using a panel of anonymous markers to identify areas of linkage in co-affected siblings. Here, we describe the principles of genome screening and update the UK survey of multiple sclerosis. This identified 20 regions of potential interest, but in none was there unequivocal linkage. In theory, attempting to replicate these findings in a second set of sibling pair families is the most appropriate way to distinguish true from false positives, but unfortunately the number of families required to do this reliably is prohibitively large. We used three approaches to increase the definition achieved by the screen: (i) the number of sibling pairs typed in an identified region of potential linkage was extended; (ii) the information extraction was increased in an identified region; and (iii) a search was made for missed regions of potential linkage. Each of these approaches has considerable limitations. A chromosome-by-chromosome
Introduction
Multiple sclerosis results from the interplay of environmental and genetic factors but it does not follow a predictable pattern of inheritance and cannot yet be explained mechanistically
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account is given to direct future searches. Although an additional marker placed distal to the 'hit' on chromosome 14q increased linkage in this area, and typing extra sibling pairs increased linkage on chromosomes 6p and 17q, evidence for linkage was more commonly reduced and no additional regions of interest were found. A further refinement of the genome screen was undertaken by conditioning for the presence of HLA-DR15. This produced a surprising degree of segregation among the regions of interest, which divided into two distinct groups depending on DR15 sharing: the DR15-sharing cohort comprised loci on chromosomal areas 1p, 17q and X; and the DR15-non-sharing cohort was made up of loci on 1cen, 3p, 7p, 14q and 22q. This result further highlights the genetic complexity of multiple sclerosis. What can now be inferred is that a gene of major effect is excluded from 95% of the genome and one with a moderate role from 65%, whereas genes which make a very small biological contribution cannot be discounted from any region. The available results suggest that multiple sclerosis depends on independent or epistatic effects of several genes each with small individual effects, rather than a very few genes of major biological importance.
through an effect of definable gene products or functional abnormalities, although both may exist. In all these respects multiple sclerosis is a typical complex genetic trait.
Background from pedigree analysis
In the 1950s, neurologists first systematically documented familial clustering of multiple sclerosis, revealing that~20% of patients have one or more affected relatives (Pratt et al., 1951) . Building on this observation, the last decade has seen definitive studies of recurrence risks in informative groups of family members. These studies represent an enormous amount of field work, and although some have incorporated flaws in design or analysis their results can usefully be summarized as follows: compared with the lifetime risk for northern European Caucasians (~1 : 300), there is an increased relative risk (λ) for identical twins [λ ϭ 100-190 (Sadovnick et al., 1993; Mumford et al., 1994) ], full siblings [λ ϭ 13 (Robertson et al., 1996) ], half siblings [λ ϭ 7 (Sadovnick et al., 1996) ], other first-degree (λ ϭ 7) and second-degree (λ ϭ 3.5) relatives (Robertson et al., 1996) , and the children of single affected parents [λ ϭ 5.5 (Robertson et al., 1996) ] and conjugal parents [λ ϭ 60 (Robertson et al., 1997) ], but not adoptees [λ ϭ 1 (Ebers et al., 1995) ]; further evidence for a genetic contribution to causation is provided by similar age at onset within multiplex families (Doolittle et al., 1990; Bulman et al., 1991b) .
At the same time, phenotypic and genotypic studies have sought to identify, both in population association and linkage studies, factors which confer an increased risk of disease and which, alone or in combination, might account for the heritability apparent from pedigree analysis. These candidate gene studies have had a disappointingly low yield, showing an association only with the class II major histocompatibility complex (MHC)/human leukocyte antigen (HLA) haplotype DRB1*1501-DQA1*0102-DQB1*0602 (Olerup and Hillert, 1991) . A variety of other candidates encoded within the MHC have been assessed, with variable results, including tumour necrosis factors (TNF) α and β, peptide transporters (TAP 1 and TAP 2) and class III MHC products (see, for example, Bulman et al., 1991a; Kellar-Wood et al., 1994a; Roth et al., 1994; Sandberg-Wollheim et al., 1995) . Outwith the MHC, loci which have been explored include the genes for myelin basic protein (Tienari et al., 1992; Graham et al., 1993; Rose et al., 1993; Eoli et al., 1994a; Wood et al., 1994) , the immunoglobulin heavy chain cluster (Walter et al., 1991; Hashimoto et al., 1993; Hillert, 1993; Yu et al., 1993; Wood et al., 1995a; Wansen et al., 1997) and the T-cell receptor α (Hashimoto et al., 1992; Hillert et al., 1992; Eoli et al., 1994b) and β chains (Seboun et al., 1989; Charmley et al., 1991; Lynch et al., 1991; Beall et al., 1993; Wood et al., 1995b) . Mutations of mitochondrial DNA do not appear to contribute to susceptibility in typical patients with multiple sclerosis but identify individuals characterized by early bilateral visual failure; this example provides the first definite evidence for disease heterogeneity in multiple sclerosis .
The failure of these candidate gene studies to account for the heritability implicit from classical studies added impetus to the genome-wide searches, with the combined aims of strengthening the evidence for involvement of those loci which had provisionally been implicated and identifying new regions of interest.
Given this situation, we and others decided to carry out a full genome search in multiple sclerosis, these being the first full such attempts in the context of a complex neurological disease (Ebers et al., 1996; Haines et al., 1996; Sawcer et al., 1996) . Here, we review the background and principles behind these screens, and update the result of the UK study, which has now been augmented by increasing the number of families and the density of markers typed in selected regions of interest, and by MHC conditioning, since this locus shows the most consistent evidence for linkage in all three screens.
Linkage and association
In principle, there are two methods for mapping susceptibility loci. The first is by searching for markers which co-segregate with the disease within families (linkage), and the second is by identifying markers with allele frequencies that differ in individuals with the disease compared with those without (association). Linkage carries the advantage over association studies that, in general, it extends over greater genetic distances and may therefore be detected using fewer markers. Conversely, association has the advantage that it is considerably more powerful than linkage for genes of small effect and therefore requires smaller study populations. Linkage may be sought within extended pedigrees by counting recombinant and non-recombinant meioses (classical linkage analysis), or within simpler pedigrees by searching for regions of the genome shared by affected individuals (affected pair analysis). Association may be sought by comparing unrelated cases and controls (population association studies) or by comparing within families the parental alleles transmitted to an affected individual with the parental alleles not transmitted to that individual (transmission studies; Fig. 1 ).
Sibling pair linkage has been used extensively in the analysis of complex traits because the numerical expectations are predictable. The elegance of the method is that it requires a minimum of two affected siblings who definitely have the trait (disease) according to agreed criteria; the availability of parents, sample size and disease heterogeneity then influence the power of the available clinical resource to resolve the location of susceptibility genes.
Genotypes can be tested for similarity in two ways ( Fig. 1 ): alleles are either identical by state-a situation in which similarities may or may not result from inheritance of the marker allele on the same ancestral chromosome-or identical by descent, in which case parental samples are used to prove that the markers are part of the same haplotype as that which includes the putative susceptibility gene. Given identity by state, identity by descent can also be deduced by constructing parental haplotypes once the frequency of polymorphisms encoded at each locus is known (Holmans, 1993) . In identity by descent analysis, the expected sharing of transmitted alleles between siblings under the null hypothesis is 1/4, Fig. 1 This fictitious pedigree demonstrates the principles behind linkage analysis and association. At locus 1 each parent is heterozygous and there are no shared alleles (1, 2, 3 and 4). At locus 2 each parent is heterozygous but both have allele A. Situation I illustrates the sharing probabilities identical by descent at locus 1. Situation II illustrates transmission of parental alleles also at locus 1. Situation III illustrates circumstances under which two siblings identical by state at locus 2 are or are not also identical by descent.
1/2 and 1/4 for 0, 1 and 2 alleles (Z0, Z1, Z2), respectively; deviation away from this ratio suggests linkage to the disease trait (Suarez et al., 1978) . With the development of microsatellite polymorphic markers (see below) it has become easier to assign the complete identity by state and descent profiles within families; these concepts are enshrined in computer programs such as SPLINK [version 1.05 (Holmans and Clayton, 1995) ] and MAPMAKER/SIBS [version 1.0 (Kruglyak and Lander, 1995) ], which underpin current linkage map derivation. The obverse to linkage is exclusion; this provides a statement on whether a part of the genome can safely be excluded from harbouring genes of defined effects, and a critical threshold is considered to be a lod score less than -2 (Ott, 1991) . Exclusion maps vary with the estimated magnitude of the genetic effect contributed by each locus and the process of exclusion is constrained by preset models of inheritance-assumptions which may turn out not to be correct.
Principles of genome screening
The principle requirements for linkage genome screening in complex traits are a sizeable and well validated clinical resource, a map of highly polymorphic markers covering the whole genome and the technology to complete the large number of genotypings required. It was the discovery of widespread short sequence repeats [variable number of tandem repeats (Nakamura et al., 1987) ] and subsequently CA n (cytosine-adenosine) repeat microsatellites (Weber and May, 1989) , together with their fluorescent labelling, sizing (Diehl et al., 1990; Ziegle et al., 1992) and mapping within the human genome (Dib et al., 1996) , that enabled genome screening to develop.
The first genome screen in a complex human disease (insulin-dependent diabetes) was reported in 1994 (Davies et al., 1994) . Since then, studies in a variety of conditions, both rare and common, have been reported and the list now includes schizophrenia (Moises et al., 1995) , bipolar affective disorder (Blackwood et al., 1996; Ginns et al., 1996; Stine et al., 1997; Rice et al., 1997) , asthma (Daniels et al., 1996) , inflammatory bowel disease (Satsangi et al., 1996) , prostate cancer (Smith et al., 1996) , psoriasis (Matthews et al., 1996) , non-insulin-dependent diabetes (Mahtani et al., 1996) , hereditary sensory neuropathy type 1 (Nicholson et al., 1996) , ataxia-telangiectasia variant (Saar et al., 1997) and obesity (Comuzzie et al., 1997) .
Some authors (Elston, 1992; Hauser et al., 1996) have pointed out that the considerable genotyping effort involved in genome screening can most efficiently be undertaken using a two-staged approach, where the first stage involves screening the whole genome in a moderately sized population and the second stage requires further families to be typed in those regions showing potential linkage. This method is efficient since the typing effort is concentrated just in those areas that the initial screen identifies as the most likely sites for linkage. The disadvantage of using a small sample in the first stage is that many false positives will need to be followed up. However, typing extra families at these false-positive loci requires less effort than typing many more families across the whole genome. The second stage is a replication step and is calculated to require approximately n -1 times as many sibling pairs as were involved in the first stage [where n is the putative number of susceptibility genes (Suarez et al., 1994) ]. If a five-locus model is assumed for multiple sclerosis, 650 families would be needed to detect a gene of moderate effect, and this is greater than the number which can easily be gathered by most single centres; however, this number of families is now available on a worldwide basis notwithstanding the confounding effects of ethnic differences. Failure to reproduce results between as opposed to within populations can also be explained by the relatively small cohort sizes of each. This has been starkly evident in the field of psychiatric disorders. In bipolar disease, 14 regions were found with lod scores suggestive of linkage, and though some have been implicated more than once none can safely be regarded as 'established' (see above). The reasons for this have been discussed by Risch and Botstein (1996) , but paramount is the issue of genetic complexity, in which genotypes and their products interact variably with the surrounding environment to cause the disease phenotype. Any supposition about modelling this relationship is highly unpredictable, considerably increasing the sample size needed to overcome power limitations and raising the question of whether genome screening, which has such a small dividend, merits the effort required. Since any single study is unlikely to be definitive, meta-analysis may well be needed to extract the maximal available information.
The UK genome screen: methods

Clinical resource
This study is based on a cohort of 428 sibling families, but the register remains open and currently lists 544 index cases. The protocol for ascertainment and incorporation of these pedigrees has been described (Robertson et al., 1996) . Of paramount importance in affected sibling-pair work is the knowledge that siblings actually have the trait under investigation (or, if this is heterogeneous in its phenotype, that uniform definitions of inclusion and exclusion criteria have been agreed in advance) in order to avoid diluting the statistical power of the study. Careful attention was paid in the UK genome screen to application of the Poser criteria (Poser et al., 1983) . Within each sibship, one individual had to meet the Poser criteria for clinically definite disease (Poser A) . In the event, all except two siblings were classified as having clinically or laboratory-supported definite (A and B) or clinically probable disease (C); the two who were initially classified as having laboratory-supported probable disease (D) now have clinically definite multiple sclerosis (A). Strenuous efforts were also made, using clinical criteria and available paraclinical investigations, to identify families with conditions known to mimic multiple sclerosis, such as the hereditary paraplegias or ataxias, and this criterion led to the exclusion of 54 families. Another 147 were not included for logistical reasons (usually because one sibling was dead or unwilling to participate).
The organization involved in identifying and validating a clinical cohort for genome screening in a complex trait should not be underestimated. At the inception of our survey, only 129 families were available (set 1) but a second cohort of 98 families was then collected (set 2). The pedigree structures of the sibling families on whom genotyping was performed are summarized in Table 1 ; as is the usual practice, trios were included in order to maximize the effective number of pairs. The validity of weighting trios is not finally resolved; strictly, each provides only two fully independent pairs, although this restriction reduces the information available (Blackwelder and Elston, 1985) . In practice this was not a major issue since trios made up only 5% of our total sibling population.
Genotyping
DNA was extracted from venous blood leukocytes using standard techniques and adjusted to a working concentration of 10 ng/µl. Microsatellite polymerase chain reaction (PCR) was performed with an initial touchdown phase over 10 cycles (Don et al., 1991) followed by 17-20 cycles with 1 min denaturing at 94°C, 1 min annealing at temperatures between 50 and 55°C and 45 s extension at 72°C; a final 10 min extension step was performed at 72°C. The PCR products were then multiplexed together in predefined sets before gel electrophoresis. Electrophoresis was carried out using an Applied Biosystems Division (ABI) 373A sequencing machine, with typing accomplished using the semi-automated GENESCAN™/GENOTYPER™ system (Reed et al., 1994) . The GENESCAN TM process is an automated system that collects, sizes and quantifies DNA fragments by fluorescence detection. Each lane contains an internal size standard for precise base size calling; this is achieved by creating a calibration curve of peak arrival time which is used automatically to determine the length of an unknown PCR product. As a fragment passes into the scanning region, a laser excites fluorescence within the dye label attached to this product and a photomultiplier tube converts this fluorescent light into an electrical signal, which is then stored in computer form. In total 353 markers have now been applied to the UK sibling resource, and our web site (http://neuro.jesus.cam.ac.uk/neurology/genetics/) provides full details of their primer sequences and optimization conditions, together with full results based on the most recently updated genotypes (see below).
Fine HLA analysis based on the PCR was carried out using primers designed to detect all phenotypically expressed DRB1, DQB1 and DQA1 alleles (19, 19 and 10, respectively (Olerup and Zetterquist, 1992; Olerup et al., 1993) . The conditions were 2 min at 94°C, followed by 10 cycles of 20 s at 94°C, 60 s at 65°C, 60 s at 94°C, followed by 20 cycles of 50 s at 61°C, 30 s at 72°C. The amplified products were visualized under ultraviolet light on a 3% agarose gel containing 0.5 mg/ml of ethidium bromide at 180 V for 40 min.
Statistical analysis
The results produced from GENESCAN TM were imported into GENOTYPER 1.0 TM and the internal size standards were discarded. In the first stage, all microsatellite peaks that fell between predefined size ranges were labelled. The validity of the computer-generated labels was checked by hand to avoid artefact peaks being labelled. Thus, a table was constructed depicting for each individual, at each marker site, the sizes of the alleles found. For each microsatellite, a range of alleles, distinguished by size, was produced for this sibling population. The dataset was run through the SPLINK program to derive single-point lod scores, to ascertain the behaviour of each marker and to produce a set of allele frequencies for this population. The main workhorse of the final phase is MAPMAKER/SIBS, which analyses qualitative and quantitative data and produces maximum lod scores (MLS), information extraction and exclusion maps. MAPMAKER/ SIBS can handle unknown parental genotypes and performs its function using all the genotypic information from the chromosome to infer the full probability distribution of the identity by descent status at every point.
Transmission disequilibrium testing of the HLA data was provided by the sib_tdt program of Risch's ASPEX package, which simply ascertains the numbers of transmissions and non-transmissions of each allele and uses a χ 2 test to determine the statistical significance of the deviation. The most likely haplotypes on chromosome 6 were calculated using the GENEHUNTER program.
UK genome screen: updated results
The UK genome screen in multiple sclerosis evolved gradually as more sibling pairs became available and extra genetic markers were applied to this clinical resource. Table 1 Chromosome X. Fig. 2 Chromosomal analysis of the UK screen in multiple sclerosis. MLS (constrained to the 'possible triangle') and exclusion values for each marker are given. The dotted line represents a nominal 5% significance value as calculated for the stage 1 data only (for details, see Sawcer et al., 1997b) . In the exclusion graphs any point below -2 is considered to be excluded under a no-dominance model; λ parameters of 5, 2 and 1.2 are plotted (blue, green and red curves, respectively). Unresolved markers share the same tick. Markers not otherwise identified (such as D1S214) were typed only in the first set of 129 families. Those marked with a single asterisk (*) were also typed in stage (1 and) 2 of the screen and have been published previously (Sawcer et al., 1996) . Markers with two asterisks (**) were typed in stage 1 and 2 but have not been published previously. Markers with a § were typed only in stage 3 and are also previously unpublished. The marker order and separations are taken from the Généthon map in the first instance and from Davies et al. (1994) for those not positioned on the Généthon map. RFLP is an RFLP haplotype in the immunoglobulin heavy chain gene cluster. On the X chromosome, the MLS is the sum of the MLS calculated for each of the three gender groups (brother-brother, sister-sister and brother-sister). details the overall strategy, which now comprises three stages: stage 1, the initial phase of the genome screen with 311 markers (panel 1) applied to the first set of siblings; stage 2, in which a second set of sibling families was added and typed on a subset of these panel 1 markers (69); stage 3, exploring key areas, in which a new panel of 42 markers was typed on both sets 1 and 2. The whole endeavour has been augmented by carrying out HLA conditioning on stages 1 and 2. As well as the logistical difficulty of collecting the sibling clinical resource, the effort involved in typing and analysing should not be disregarded; there were 140 000 separate PCR reactions in stage 1, 15 000 in stage 2 and 36 500 in stage 3, making a total of Ͼ190 000 genotypes.
An individual chromosome-by-chromosome summary of the current results of the UK genome screen is given in Fig. 2 . For each chromosome, this shows a multipoint map of the MLS (labelled with §). The 5% probability values based on computer simulations (stage 1 data) of our families and markers are plotted as a dotted black horizontal line; peaks above this limit remain regions of interest. For each chromosome, exclusion maps for genes possessing λ scores of 5, 2 and 1.2 are also plotted under a model of nodominance variance. It follows that regions with high MLS values will overlap with those where a gene of major or moderate effect cannot be excluded. But this is not invariably true since, unlike the exclusion maps, the MLS is not constrained by assumptions on the mode of inheritance. For example, the left and right peaks on chromosome 1 (D1S199 and D1S236) have identical MLS values but different exclusion patterns; a gene of major biological importance cannot be excluded (under the model of no-dominance variance) at D1S199 but is very unlikely at D1S236. These comparisons allow tentative conclusions to be reached concerning the location and mode of inheritance for putative susceptibility genes within regions of interest. The additions to each chromosome from our previous publication are as follows, with suggested candidates highlighted from within and around each region of interest using the On-Line Mendelian Inheritance in Man (OMIM) database at http://www3.ncbi.nlm.nin.gov/omim/ and Genome Database (GDB) at http://www.gdb.org/. Chromosome 1. Initial genome screen: two MLS maxima were identified at 1p and 1cen, respectively; the latter, though broad, touched an MLS of 2.0 (the 1cen markers were typed in both sibling sets); updated results: the 1p markers have now been typed on the second set and fail to alter the shape of this MLS curve; the addition of two telomeric markers has not revealed any hidden areas of interest; potential candidate genes: connexin 40, TNF receptor-2, complement components 1 and 8 (β component), janus kinase 1, nerve growth factor β, endothelin converting enzyme, vascular cell adhesion molecule-1; verdict: both regions remain open as the exclusion maps confirm; however, the genetic distance involved (~130 cM) is enormous. Chromosome 2. Initial genome screen: some initial interest was apparent at 2cen with an MLS just crossing the nominal 5% significance level; updated results: six of the markers lying in this region have been further typed in set 2 and the MLS fell to~0.5; verdict: the fall in MLS represents regression to the mean but this 2cen region remains of potential interest. Chromosome 3. Initial genome screen: a 3p/3cen area appeared possible with an MLS around 1.3; updated results: the six markers lying under this peak have now been applied to the second set of siblings, with little change; verdict: a susceptibility gene cannot be excluded, although it is not especially promising. Chromosome 4. Initial genome screen: this produced a high distal 4q result over four of the microsatellites; updated results: applying these four microsatellites to the second sibling set has reduced the MLS value; verdict: remains possible in much the same way as chromosomes 2 and 3, but unpromising. Chromosome 5. Initial genome screen: a major area of interest in the short arm/centromeric region was highlighted in all three genome screens; in addition, building on recent evidence from a genome screen carried out in the murine model experimental autoimmune encephalomyelitis (EAE) which declared potential regions of interest to be the syntenic areas 5p12-14, 1p and Xq13-22, Kuokkanen et al. (1996) explored these in a Finnish population and demonstrated linkage to the 5p locus (though not the others); updated results: this zone was explored in detail in order to investigate the relative efficiencies of typing varying densities of markers. As expected, after analysis with marker maps at 12, 8, 4, 2 and 1 cM densities in all 251 sibling pairs, additional information extraction was shown to be relatively inefficient with increasing marker density; potential candidate genes: complement components 6, 7 and 9, interleukin cluster, interleukin 6 signal transducer, interleukin 7 receptor, survival motor neuron gene, glial cell line-derived neurotrophic factor, microtubule-associated protein 1B; verdict: though the current linkage score is not outstanding, the exclusion map still points to this being a potential location for susceptibility gene(s), particularly when combined with evidence for replication from independent data sets. Chromosome 6. Initial genome screen: 6p21 as a principal area of linkage was highlighted, significant transmission disequilibrium occurring with one TNFα allele; updated results: initially two additional markers were placed to explore further the q arm, and no change occurred; potential candidate genes: MHC, myelin oligodendrocyte glycoprotein, TNFα, peptide transporters TAP 1 and 2, complement components 2 and 4, spinocerebellar ataxia 1; verdict: chromosome 6p encodes the MHC and with the previously known population association can be considered as proven. Chromosome 7. Initial genome screen: a substantial peak was revealed on the 7p arm in the first stage of the screen; adding the second set of siblings had little effect; updated results: no further markers have been typed; potential candidate genes: interleukin 6, platelet-derived growth factor (α chain), T-cell antigen receptor (γ polypeptide), epidermal growth factor receptor; verdict: remains promising. updated results: the use of a telomeric marker increased exclusion and left the MLS largely unchanged at a nonsignificant level; verdict: unlikely to encode susceptibility genes. Chromosome 22. Initial genome screen: a peak was found in the pericentromeric domain, but this MLS fell in the second stage; updated results: one unremarkable telomeric marker; potential candidate genes: neurofilament heavy polypeptide, tissue inhibitor of metalloproteinase 3, interleukin 2 receptor (β chain), crystallin β (B1 and B2); verdict: remains possible, although the exclusion map suggests only a gene of small effect. Chromosome X. Initial genome screen: the most promising effect was seen in the male-male pairs, suggesting a possible X-linked dominant effect; updated results: marker Dϫ943 was retyped in the second sibling set without altering the previous findings; potential candidate genes: interleukin-2 receptor γ subunit, proteolipid protein, adrenoleukodystrophy gene, interleukin 9 receptor, L1 cell adhesion molecule; verdict: warrants further investigation.
Overall conclusions from the random genome screen Stage 1
MLS mapped in the initial screen did not demonstrate any region of unequivocal linkage. Given the power of the study reliably to detect genes of large effect (λ Ͼ 3.0), this finding provides substantial evidence for the absence of such a gene(s). Although disappointing, this result is useful and important. When combined with what is known concerning the epidemiology of multiple sclerosis, one interpretation is that susceptibility results from the interaction of many genes, each exerting only modest effects. An immediate question is the significance, if any, of these observed MLS peaks. Theoretical asymptotic P values can be assigned to each (Holmans, 1993) . In addition, these P values are nominal (point-wise) significance levels and therefore make no allowance for the multiple testing involved in a whole genome screen. Lander and Kruglyak (1995) have published guidelines for the interpretation of linkage results obtained in genome screens, which include specific lod score thresholds for declaring results as suggestive or significant on a genomewide basis. In order to avoid uncertainties about these new theoretically calculated thresholds, we used simulations to obtain empirical point-wise and genome-wide P values (Sawcer et al., 1997b) . In stage 1, the equivalent number of fully informative families was 74 and the average separation of markers was 12 cM. If an oligogenic model of five loci is assumed, stage 1 has high power to detect at least some of the loci at MLS Ͼ 0.7, reasonable power at MLS Ͼ 1.8 and little power at MLS Ͼ 3.2. As a caveat, MLS values of 1.8 and 0.7 for the expectation of one false positive per genome screen and the lod score providing a 5% nominal value for any single point may be underestimates where the density of markers has been selectively increased around a region of provisional linkage.
Stage 2
The failure to demonstrate significant linkage despite the addition of set 2 sibling pairs for markers from the most promising hits in stage 1 provides further support for the conclusion that no autosomal loci for multiple sclerosis exist which exert more than a moderate effect. The possible Xlinked effect is, in principle, an exception; however, the problem here is that only brother-brother pairs have the power to detect an X-linked dominant effect and these form a small proportion of multiple sclerosis sibling pairs, making it very much harder to collect the resource necessary for a definitive study.
Despite finding no significant linkages, the approach can be viewed as successful since it has identified those regions which are likely to encode at least some of the important genes and has narrowed down the area in which further searches can now concentrate. A search for transmission disequilibrium is logically the next approach (as has been described above) and, as a first step towards this, evidence was sought at each of the nine markers from the two regions where evidence for linkage had increased with the addition of the stage 2 families; the analysis was performed only for alleles with a frequency of Ͼ10%. As previously reported, the 121 base pair (bp) allele of the TNF-α marker (on 6p21) showed significant evidence of excess transmission, with χ 2 (1) ϭ 17.0 (P Ͻ 0.00004). In addition, the 222 bp allele of the flanking marker D6S276 also showed evidence for excess transmission, as did the 138 bp allele of the other flanking marker, D6S273; by coincidence, in each case, the χ 2 (1) ϭ 6.6 (P Ͻ 0.01). This result is not surprising since association with the MHC region is well known; however, it confirms that not only does the study have the power to detect small effects but also that it was conducted with sufficient accuracy not to have missed such effects through error. Transmission disequilibrium testing on 17q22 also demonstrated some evidence for association, but care must be taken with the interpretation in view of the number of tests carried out on a large number of alleles.
Stage 3
The third stage had two purposes: to continue the stage 2 process of examining regions of interest in more detail and to fill in the sparsely covered telomeres from the first two stages. Generalizing from the chromosome-by-chromosome analysis above, it can be seen that, in some areas of the genome, the addition of extra markers heightened the interest in a region (particularly 14q and perhaps 17q); in others areas it had little effect in better defining the region (1p, 3p/cen, 5cen and 6q); and in a final group the effect was to reduce the probability of having identified a region encoding a gene which confers significant susceptibility (2cen and 4q). Moreover, importantly, increasing the density of genetic markers lying between 4 cM (17q22) and 1 cM (5p14) did not increase the precision with which the significant MLS at those stations can be defined: i.e. use of a linkage-based technique on this cohort could not refine the cartography further, in agreement with the experience of other groups.
One concern we had was that telomeric areas which were under-represented in stage 1 might include loci important for conferring susceptibility to multiple sclerosis; therefore, 11 markers were used to explore these termini. The result was in a sense reassuring, i.e. no new regions of interest were revealed and, apart from the sector coding for the immunoglobulin heavy chain (which had been already highlighted from stage 1), and perhaps 4q, no telomeres seem to be implicated in the genetics of multiple sclerosis.
Stage 3 now allows an up-to-date computation of those areas which are essentially excluded: indeed, these provide the most reliable guide to future searches (with the proviso that they are influenced by assumptions on models of inheritance). We would not expect chromosomes 8, 9, 10, 15, 18, 20 and 22 to be involved in biologically significant genetic susceptibility to multiple sclerosis, for in all of them genes with individual λ values of 5 and 2 have been excluded, although of course there still exists the possibility that they harbour genes of small effect (λ ϭ 1.2) since on no chromosome is such a gene completely excluded (i.e. the exclusion graph does not fall below -2 along its entirety), with the possible exception of chromosome 8. In summary, exclusion has now risen to 95% of the genome for genes of large effect (λ ϭ 5) and to 65% for those of moderate effect (λ ϭ 2). Conversely, we can only exclude genes contributing a small biological effect (λ ϭ 1.2) from a tiny fraction (0.03%) of the genome.
Class II MHC stratification
There is another potential reason for our failure to resolve the genetics of multiple sclerosis implicated by pedigree analysis using systematic genome screening. It lies in the possibility that the identity and combination of genes involved in different families is not the same. In this context of genetic heterogeneity, the 'multiple sclerosis phenotype' would be produced by a variety of genotype permutations. This potential genotype-phenotype mismatch was explored, in a preliminary way, by stratification of the analysis on the basis of sharing the DR15 phenotype (Fig. 3) . In order to investigate further the possible significance of segregations seen in the conditional analyses, we used transmission disequilibrium testing within the corresponding population to look for evidence of linkage disequilibrium across these regions. Three markers closest to the peak MLS in each of the 10 segregating regions were considered and, for each, the three commonest alleles were tested. The results for those alleles that showed a significant distortion in transmission (P Ͻ 5%) are shown in Table 2 . Although these results are not significant when allowance is made for multiple testing, they do further support the notion of heterogeneity in the genetics of multiple sclerosis.
In the absence of epistatic effects, conditioning the analysis for sharing at one linkage point should segregate MLS at the remaining linkages in the same proportions as the sample is split. In fact, conditioning for HLA produces a clear separation of the observed potential linkages. Some cluster with the DR15-sharing families (1p, 17p, 17q and X) and others with the non-DR15-sharing families (1cen, 3p, 7p, 14q and 22q). A further potential dividend from conditioning the analysis is that regions which do not show any evidence for linkage to multiple sclerosis using all available families (see above) may emerge as linked to the disease in one or other of the stratified groups. We found evidence for linkage on 5q and 13p in the DR15-sharing families and linkage on 16p and 20p in the non-DR15-sharing families; these are not regions previously implicated as potential susceptibility loci in multiple sclerosis. Furthermore, conditioning for DR15 may resolve broad sections of apparent linkage into discrete regions of interest; this is well shown on chromosome 1.
Discussion
Three whole genome screens involving patients with multiple sclerosis were published in 1996; each offered certain differences in family structure, genotyping protocols, methods of analysis and conclusions (for review see Sawcer et al., 1997a) . Kuokkanen et al. (1997) have since reported their analysis of a genome-wide screen in 16 Finnish families using 328 markers which revealed no statistically significant areas of interest, although positive lod scores were obtained for 6p21 (MHC) and 5p14-p12; increasing marker density altered the lod scores in several other regions (4cen, 11tel and 17q), whereas others (2q32 and 1q21) were unchanged. When all 21 families were typed across the regions of interest, 17q22-q24 showed the highest lod score (2.8).
The prominence of the MHC region on 6p21 is confirmed but, in one sense, this merely establishes an old finding and the question could rightly be asked whether this is a sufficient dividend from all the effort involved in a full genome screen. Clearly the observation serves as a positive control for the whole approach, indicating that the method is robust and can show effects which are known to exist, therefore providing confidence that some (at least) of the new findings are also true positives. In this spirit, it is apparent that several novel regions have been identified, not with the same certainty as exists with monogenic disease but with a reasonable degree of cross-cultural reproducibility. A number of lessons can be learned from these experiments. Foremost is the question of power; a large number of sibling pairs is needed to demonstrate and then replicate any genetic findings-undoubtedly closer to 1000 than 100 sibling pairs. In addition, we would argue that applying ever more dense sets of markers to a cohort of families does not help to narrow potential domains. The effects of increasing marker map density have been explored by others in both a theoretical (Hauser et al., 1996; Holmans and Craddock, 1997) and an experimental sense . Using computer simulation, the first two groups suggested that in terms of marker density, the most efficient way to type sibling pairs is with a 10-20 cM map and then to follow up regions of interest; for example, increasing the density from 10 to 2 cM changed the MLS from 6 to 8 in one simulation (Hauser et al., 1996) . Similarly, saturation mapping of 6q in an effort to fine-map susceptibility genes in type 1 diabetes increased the MLS from 2.2 to 2.4 for a change in marker density from 8 to 2.5 cM . Thus, although the temptation is to carry on typing more and more markers over a region of interest, previous and current experience suggests that, unless the actual sibling population is dramatically expanded, there is unlikely to be a useful dividend from the effort involved. It is for this reason that we have invested time since completion of the full genome screen in identifying and validating a resource of over 750 simplex families consisting of a proband (with additional affected siblings when possible) and both parents (usually unaffected but the clinical status is not important) for transmission disequilibrium testing. We are now ready to screen regions/ genes of interest for allelic association using a resource which we consider to be of sufficient statistical power to identify genes of moderate effect.
A one-stage approach to solving the genetic basis of multiple sclerosis through the study of candidate loci using linkage or population association methods did not succeed, and this in turn stimulated the need for systematic genome screening. This too, as it has turned out, failed to solve the genetic component to multiple sclerosis. Full characterization will proceed slowly, but at least the initial search has been useful in focusing on regions of interest which would not have received attention without prior identification in the random genome screen approach. From an increasingly sophisticated knowledge of the pathogenesis of multiple sclerosis, it is now possible to select new candidates and use these exclusion maps to assess the potential relevance of these loci. Some may eventually prove disappointing and, conversely, genes may yet exist which encode polymorphic products but are not encoded within regions of interest. We believe that the eventual application of the genetic analysis lies more in the elucidation of pathogenic mechanisms than in diagnostic or prognostic clinical application and in the dissection of disease heterogeneity. We also predict that misinformed selection of new candidates outside areas demonstrated from genome screening is a high-risk strategy for identifying susceptibility genes compared with the imaginative use of information based on the understanding of the pathogenesis in combination with the systematic genetic analysis-the positional candidate gene approach.
It remains possible that failure to account for a significant proportion of the heritability of multiple sclerosis through existing genome screening efforts is, by bad luck, because all screens have missed a major locus in the interval between flanking markers or at some region, such as the telomere, which has been underscrutinized. An alternative explanation is of multiple independent effects, all of small magnitude. However, we favour disease heterogeneity as the best explanation for the present failure of the 10 cM map to resolve the genetics of multiple sclerosis. Even now, we can begin to speculate on different steps in the pathogenesis which depend primarily on T-cell-dependent (DR15-sharing) or antibody-mediated (DR15-non-sharing, 14q-linked) mechanisms with different pathogenic models converging on the indistinguishable phenotype of clinically definite multiple sclerosis.
